ClinicalTrials.gg
CompletedNCT00210431Updated Mar 31, 2020

Post Marketing Surveillance Study of Dysport

An observational study in Blepharospasm, Hemifacial Spasm and Cervical Dystonia, sponsored by Ipsen. Completed at 36 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2020-03-31.

Sponsored by Ipsen · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
783
Ages
2 Years and older
Sex
All
01

Study summary

The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.

02

Conditions studied

  • Blepharospasm
  • Hemifacial Spasm
  • Cervical Dystonia
  • Spasmodic Torticollis
  • Cerebral Palsy
  • Muscle Spasticity
  • Cerebrovascular Accident
  • Equinus Deformity
  • Facial Hyperdynamic Lines
03

In context

Blepharospasm

42 studies on the registry are indexed under Blepharospasm; 1 is open to participants now.

This study's enrollment of 783 is above the median of 115 across 14 observational studies indexed under Blepharospasm.

Browse Blepharospasm studies →

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult or child over the age of 2 years
  • scheduled to receive Dysport as per their normal treatment practice, and in conformance with their country's Summary of Product Characteristics

Exclusion criteria

Exclusion Criteria:

  • history of to Dysport or drugs with a similar chemical structure
  • treatment with any other drug within the last 30 days before survey entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
783 participants (actual)
06

What researchers measure

Primary outcomes

  1. - assessment of efficacy as assessed by treating physician at scheduled follow up visit

  2. - data on adverse events since treatment with Dysport

07

Study locations

36 sites
  • Centre Hospitalier Saint Esprit
    Agen, 47923, France
  • Center Hospitalier du Pays d'Aix
    Aix en Provence, 13616, France
  • Centre Hospitalier
    Chambery, 73011, France
  • Hopital Timone Adultes
    Marseille, 13385, France
  • Hopital Central
    Nancy, 54035, France
  • Hopital Hotel Dieu
    Nantes, 44093, France
  • Hopital Pasteur
    Nice, 06002, France
  • Hopital Caremeau
    Nimes, 30029, France
  • Hopital Saint Antione
    Paris, 75571, France
  • Centre Hospitalier Pitie Salpetriere
    Paris, 75651, France
  • Hopital Sainte Anne
    Paris, 75674, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • CHU Charles Nicolle
    Rouen, 76031, France
  • Hopital Bellevue
    Saint-Etienne, 42055, France
  • Hopital Civil
    Strasbourg, 67091, France
  • Hopital Purpan
    Toulouse, 31059, France
  • Hopital Rangueil
    Toulouse, 31059, France
  • Praxis für Neurologie
    Berlin, 10178, Germany
  • Rhein. F.-Wilhelms-Universität
    Bonn, 53127, Germany
  • Praxis für Neurologie
    Gießen, 35390, Germany
  • Städt. Krankenhaus Martha-Maria
    Halle-Dölau, 6120, Germany
  • Neurologische Praxis
    Hamburg, 20249, Germany
  • Med. Hochschule
    Hannover, 30625, Germany
  • Bürgerhospital
    Stuttgart, 70191, Germany
  • E.-Karls-Universität
    Tübingen, 72076, Germany
  • Klinikum der Stadt Villingen-Schwenningen
    Villingen-Schwenningen, 78054, Germany
  • Alma-Ata State Institute of Postgraduate Education
    Alma-Ata, Kazakhstan 480070, Russian Federation
  • Rehabilitation Centre "Balbulak"
    Alma-ata, Kazakhstan, Russian Federation
  • Centre of plastic surgery "Reconstruction and Recreation"
    Moscow, 115522, Russian Federation
  • Institute of Medical Aestetic "Vallex-M"
    Moscow, 117393, Russian Federation
  • Moscow Medical Academy
    Moscow, 119021, Russian Federation
  • Scientific Research Institute of Neurology
    Moscow, 123367, Russian Federation
  • Cosmetological Centre "Diamond"
    Moscow, 125367, Russian Federation
  • National Medical Centre of Surgery
    Moscow, 125367, Russian Federation
  • Federal Centre "Pediatric Rehabilitology"
    Moscow, 142031, Russian Federation
  • Centre for Aesthetic Dermatology and Surgery of Russian Academy of Sciences
    Moscow, Russian Federation
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00210431
Lead sponsor
Ipsen
First posted
Sep 21, 2005
Start date
Oct 2004
Completion
Jun 2006
Last update
Mar 31, 2020

Study contacts

Ipsen Medical Director
study director · Ipsen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion